Copyright
©The Author(s) 2017.
World J Gastroenterol. Aug 7, 2017; 23(29): 5379-5385
Published online Aug 7, 2017. doi: 10.3748/wjg.v23.i29.5379
Published online Aug 7, 2017. doi: 10.3748/wjg.v23.i29.5379
Figure 1 Comparison of decreased body weight (%) between patients with and without hepatocellular carcinoma.
The diuretic effect of tolvaptan was significantly higher in patients without hepatocellular carcinoma. HCC: Hepatocellular carcinoma.
- Citation: Miyazaki M, Yada M, Tanaka K, Senjyu T, Goya T, Motomura K, Kohjima M, Kato M, Masumoto A, Kotoh K. Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma. World J Gastroenterol 2017; 23(29): 5379-5385
- URL: https://www.wjgnet.com/1007-9327/full/v23/i29/5379.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i29.5379